Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer

R. J. Morgan, J. H. Doroshow, L. Leong, J. Schriber, S. Shibata, S. Forman, V. Hamasaki, K. Margolin, G. Somlo, J. Alvarnas, M. McNamara, J. Longmate, J. Raschko, W. Chow, S. Vasilev, K. McGonigle, Y. Yen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

This study was performed in order to evaluate the toxicities, progression-free and overall survival of patients with responsive residual or recurrent ovarian cancer treated with high-dose chemotherapy. Twenty-seven patients were treated. Doxorubicin, 165 mg/m2 over 96 h (days -12 to -8), etoposide 700 mg/m2 every day ×3 (days -6 to -4), and cyclophosphamide 4.2 g/m2 on d -3 was followed by stem cells and granulocyte colony-stimulating factor. The median days of granulocyte count <500/μl was 14 (range 10-42) and platelets <20 000/μl was 13 (range 2-80). Median numbers of red cell and platelet transfusions were 15 (5-16) and 14 (4-103). Toxicity included mucositis requiring narcotic analgesia in all patients. Asymptomatic decreases in ejection fraction to values <50% were observed in four patients. No clinical congestive heart failure was observed. One death due to sepsis was observed. Median progression-free survival is 7.5 months (1.0-56 months); five patients remain alive, two of whom remain progression-free at 19.5 and 24.5 months post transplant. Median overall survival is 14.0 months (1-68 months). We conclude that high-dose anthracyclines may be safely administered to ovarian cancer patients. The short overall and progression-free survivals observed in our population suggest that this combination is not optimal.

Original languageEnglish
Pages (from-to)859-863
Number of pages5
JournalBone Marrow Transplantation
Volume28
Issue number9
DOIs
Publication statusPublished - Dec 13 2001
Externally publishedYes

Fingerprint

Etoposide
Ovarian Neoplasms
Doxorubicin
Cyclophosphamide
Stem Cells
Disease-Free Survival
Platelet Transfusion
Mucositis
Anthracyclines
Narcotics
Granulocyte Colony-Stimulating Factor
Granulocytes
Analgesia
Sepsis
Blood Platelets
Heart Failure
Cell Count
Transplants
Drug Therapy
Survival

Keywords

  • High-dose chemotherapy
  • Ovarian cancer
  • Stem cell transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. / Morgan, R. J.; Doroshow, J. H.; Leong, L.; Schriber, J.; Shibata, S.; Forman, S.; Hamasaki, V.; Margolin, K.; Somlo, G.; Alvarnas, J.; McNamara, M.; Longmate, J.; Raschko, J.; Chow, W.; Vasilev, S.; McGonigle, K.; Yen, Y.

In: Bone Marrow Transplantation, Vol. 28, No. 9, 13.12.2001, p. 859-863.

Research output: Contribution to journalArticle

Morgan, RJ, Doroshow, JH, Leong, L, Schriber, J, Shibata, S, Forman, S, Hamasaki, V, Margolin, K, Somlo, G, Alvarnas, J, McNamara, M, Longmate, J, Raschko, J, Chow, W, Vasilev, S, McGonigle, K & Yen, Y 2001, 'Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer', Bone Marrow Transplantation, vol. 28, no. 9, pp. 859-863. https://doi.org/10.1038/sj.bmt.1703243
Morgan, R. J. ; Doroshow, J. H. ; Leong, L. ; Schriber, J. ; Shibata, S. ; Forman, S. ; Hamasaki, V. ; Margolin, K. ; Somlo, G. ; Alvarnas, J. ; McNamara, M. ; Longmate, J. ; Raschko, J. ; Chow, W. ; Vasilev, S. ; McGonigle, K. ; Yen, Y. / Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. In: Bone Marrow Transplantation. 2001 ; Vol. 28, No. 9. pp. 859-863.
@article{55d0cefec5774bd780cdb1e6a0eb5cab,
title = "Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer",
abstract = "This study was performed in order to evaluate the toxicities, progression-free and overall survival of patients with responsive residual or recurrent ovarian cancer treated with high-dose chemotherapy. Twenty-seven patients were treated. Doxorubicin, 165 mg/m2 over 96 h (days -12 to -8), etoposide 700 mg/m2 every day ×3 (days -6 to -4), and cyclophosphamide 4.2 g/m2 on d -3 was followed by stem cells and granulocyte colony-stimulating factor. The median days of granulocyte count <500/μl was 14 (range 10-42) and platelets <20 000/μl was 13 (range 2-80). Median numbers of red cell and platelet transfusions were 15 (5-16) and 14 (4-103). Toxicity included mucositis requiring narcotic analgesia in all patients. Asymptomatic decreases in ejection fraction to values <50{\%} were observed in four patients. No clinical congestive heart failure was observed. One death due to sepsis was observed. Median progression-free survival is 7.5 months (1.0-56 months); five patients remain alive, two of whom remain progression-free at 19.5 and 24.5 months post transplant. Median overall survival is 14.0 months (1-68 months). We conclude that high-dose anthracyclines may be safely administered to ovarian cancer patients. The short overall and progression-free survivals observed in our population suggest that this combination is not optimal.",
keywords = "High-dose chemotherapy, Ovarian cancer, Stem cell transplantation",
author = "Morgan, {R. J.} and Doroshow, {J. H.} and L. Leong and J. Schriber and S. Shibata and S. Forman and V. Hamasaki and K. Margolin and G. Somlo and J. Alvarnas and M. McNamara and J. Longmate and J. Raschko and W. Chow and S. Vasilev and K. McGonigle and Y. Yen",
year = "2001",
month = "12",
day = "13",
doi = "10.1038/sj.bmt.1703243",
language = "English",
volume = "28",
pages = "859--863",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer

AU - Morgan, R. J.

AU - Doroshow, J. H.

AU - Leong, L.

AU - Schriber, J.

AU - Shibata, S.

AU - Forman, S.

AU - Hamasaki, V.

AU - Margolin, K.

AU - Somlo, G.

AU - Alvarnas, J.

AU - McNamara, M.

AU - Longmate, J.

AU - Raschko, J.

AU - Chow, W.

AU - Vasilev, S.

AU - McGonigle, K.

AU - Yen, Y.

PY - 2001/12/13

Y1 - 2001/12/13

N2 - This study was performed in order to evaluate the toxicities, progression-free and overall survival of patients with responsive residual or recurrent ovarian cancer treated with high-dose chemotherapy. Twenty-seven patients were treated. Doxorubicin, 165 mg/m2 over 96 h (days -12 to -8), etoposide 700 mg/m2 every day ×3 (days -6 to -4), and cyclophosphamide 4.2 g/m2 on d -3 was followed by stem cells and granulocyte colony-stimulating factor. The median days of granulocyte count <500/μl was 14 (range 10-42) and platelets <20 000/μl was 13 (range 2-80). Median numbers of red cell and platelet transfusions were 15 (5-16) and 14 (4-103). Toxicity included mucositis requiring narcotic analgesia in all patients. Asymptomatic decreases in ejection fraction to values <50% were observed in four patients. No clinical congestive heart failure was observed. One death due to sepsis was observed. Median progression-free survival is 7.5 months (1.0-56 months); five patients remain alive, two of whom remain progression-free at 19.5 and 24.5 months post transplant. Median overall survival is 14.0 months (1-68 months). We conclude that high-dose anthracyclines may be safely administered to ovarian cancer patients. The short overall and progression-free survivals observed in our population suggest that this combination is not optimal.

AB - This study was performed in order to evaluate the toxicities, progression-free and overall survival of patients with responsive residual or recurrent ovarian cancer treated with high-dose chemotherapy. Twenty-seven patients were treated. Doxorubicin, 165 mg/m2 over 96 h (days -12 to -8), etoposide 700 mg/m2 every day ×3 (days -6 to -4), and cyclophosphamide 4.2 g/m2 on d -3 was followed by stem cells and granulocyte colony-stimulating factor. The median days of granulocyte count <500/μl was 14 (range 10-42) and platelets <20 000/μl was 13 (range 2-80). Median numbers of red cell and platelet transfusions were 15 (5-16) and 14 (4-103). Toxicity included mucositis requiring narcotic analgesia in all patients. Asymptomatic decreases in ejection fraction to values <50% were observed in four patients. No clinical congestive heart failure was observed. One death due to sepsis was observed. Median progression-free survival is 7.5 months (1.0-56 months); five patients remain alive, two of whom remain progression-free at 19.5 and 24.5 months post transplant. Median overall survival is 14.0 months (1-68 months). We conclude that high-dose anthracyclines may be safely administered to ovarian cancer patients. The short overall and progression-free survivals observed in our population suggest that this combination is not optimal.

KW - High-dose chemotherapy

KW - Ovarian cancer

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=0035201069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035201069&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703243

DO - 10.1038/sj.bmt.1703243

M3 - Article

VL - 28

SP - 859

EP - 863

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 9

ER -